GDF-11 (Growth Differentiation Factor 11) vs NAD+
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GDF-11 (Growth Differentiation Factor 11)
TGF-β superfamily member proposed as a 'young blood factor' — circulating GDF-11 declines with age, and young plasma transfusion in parabiosis experiments reversed aging phenotypes in mice. A high-profile but contested research area: some studies show rejuvenating effects in heart, muscle, and brain; others using purified recombinant GDF-11 show cardiac hypertrophy and muscle wasting at pharmacologic doses.
Full profileNAD+
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme essential to cellular metabolism, DNA repair, and mitochondrial function. Levels decline with age. Research focuses on restoring NAD+ through precursors (NMN, NR) or direct IV/subcutaneous administration to support longevity and energy metabolism.
Full profile| GDF-11 (Growth Differentiation Factor 11) | NAD+ | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | GDF11, Bone Morphogenetic Protein 11, BMP-11, young blood factor | Nicotinamide Adenine Dinucleotide, NAD, NAD+ precursor |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 0.1mg/kg–1mg/kg mg/kg, every 3–7 days (SC); research protocols vary widely | 250mg–1000mg mg, daily (oral precursors) or weekly/monthly (IV/SubQ) |
| Administration | Subcutaneous injection, Intravenous (research) | Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal |
| Key side effects | Cardiac hypertrophy (at pharmacologic doses — the key safety concern), Muscle wasting and weight loss, Reproductive effects (GDF-11 inhibits spermatogenesis and folliculogenesis), Cachexia-like syndrome at high doses | Flushing (especially IV), Chest tightness during rapid IV infusion, Nausea, Fatigue (transient, day of infusion) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: GDF-11 (Growth Differentiation Factor 11) is research-stage, while NAD+ is preclinical only.
- Administration: GDF-11 (Growth Differentiation Factor 11) — Subcutaneous injection, Intravenous (research); NAD+ — Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal.
- Dosing units differ: GDF-11 (Growth Differentiation Factor 11) is dosed in mg/kg, NAD+ in mg — they operate at different scales.
- Frequency: GDF-11 (Growth Differentiation Factor 11) is typically every 3–7 days (SC); research protocols vary widely; NAD+ is daily (oral precursors) or weekly/monthly (IV/SubQ).
How each works
GDF-11 (Growth Differentiation Factor 11)
The 2013–2014 parabiosis studies from Amy Wagers' lab at Harvard proposed GDF-11 as the primary rejuvenating factor in young blood. However, subsequent work by Lee and others showed that purified recombinant GDF-11 at pharmacologic doses caused cardiac hypertrophy, muscle atrophy, and weight loss — opposite of the proposed rejuvenating effects. The field now views GDF-11 as highly dose-sensitive with a narrow therapeutic window, if one exists at all.
NAD+
NAD+ is required for over 500 enzymatic reactions including those catalyzed by sirtuins (longevity-associated proteins) and PARPs (DNA repair enzymes). Rodent studies consistently show that restoring NAD+ levels reverses aspects of metabolic aging. Human trials with NAD+ precursors (NMN, NR) show improved muscle function, insulin sensitivity, and mitochondrial capacity in older adults.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.